Health promotion evaluation: recommendations to policy-makers

"In June 1995, the WHO Regional Office for Europe established a Working Group on Health Promotion Evaluation in cooperation with three government agencies: the Centers for Disease Control and Prevention, United States, Health Canada, Health Education Authority, United Kingdom. The Working Group had three objectives: to provide guidance to policy-makers and practitioners to foster the use of appropriate methods for health promotion evaluation, to examine the current range of evaluation methods, both quantitative and qualitative, and to provide guidance to policy-makers and practitioners to increase the quality of health promotion evaluations." - p. 3report of the WHO European Working Group on Health Promotion Evaluation.Publisher's no. EUR/ICP/IVST 05 01 03

Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting on 29 April 2021. Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group website. The guidance is based on the evidence in the background document on the Sinovac-CoronaVac (COVID-19) vaccine and the annexes which include the GRADE and Evidence to Recommendation tables. Both these documents are available on the SAGE COVID-19 webpage: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials. These interim recommendations refer to the inactivated vaccine against COVID-19 developed by Sinovac. The trade name of the vaccine is CoronaVac. In the subsequent text the vaccine will be referred to as Sinovac-CoronaVa

WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination

This Values Framework offers guidance globally on the allocation of COVID-19 vaccines between countries, and to offer guidance nationally on the prioritization of groups for vaccination within countries while supply is limited. The Framework is intended to be helpful to policy makers and expert advisors at the global, regional and national level as they make allocation and prioritization decisions about COVID-19 vaccines

Background document on the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19

Background document to the WHO Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listin

WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply

An approach to inform planning and subsequent recommendations based upon epidemiologic setting and vaccine supply scenario

Critical Evidence Questions For COVID-19 Vaccines Policy Making.

This document lists areas of evidence that would assist SAGE to formulate policy recommendations for consideration by WHO regarding the use of COVID-19 vaccines as they become available. It is not intended as alternative to the lists of requirements for licensure as formulated by regulatory bodies nor does it replace or provide an alternative to the WHO Target Product Profile. Rather it reflects the evidence-needs for COVID-19 vaccine policy making, based on the current scientific thinking, to assist SAGE in deciding upon the optimal use given the limited vaccine supply in order to maximise impact on the pandemic in different populations and epidemiologic setting

Interim recommendations for use of the AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID-19 developed by Oxford University and AstraZeneca

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting on 8 February 2021 (1). Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group website. These interim recommendations apply to AZD1222 (ChAdOx1-S [recombinant]) vaccine against COVID-19 developed by Oxford University (United Kingdom) and AstraZeneca as well as to ChAdOx1-S [recombinant] vaccines against COVID-19 produced by other manufacturers that rely on the AstraZeneca core clinical data, following demonstrated equivalence in their regulatory review and once emergency use listing (EUL) has been obtained from WHO. The guidance is based on the evidence summarized in the Background document on AZD1222 vaccine against COVID-19 developed by Oxford University and AstraZeneca and the Background paper on COVID-19 disease and vaccines

Guidelines for using HIV testing technologies in surveillance: selection, evaluation, and implementation

[UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance]."WHO/CDS/CSR/EDC/2001.16.""UNAIDS/01.22E.""Global surveillance of HIV/AIDS and sexually transmitted infections (STIs) is a joint effort of the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS). The UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance, initiated in November 1996, is the main coordination and implementation mechanism for UNAIDS and WHO to compile the best information available and to improve the quality of data needed for informed decision-making and planning at national, regional and global levels. ... The Centers for Disease Control and Prevention (CDC), Atlanta, USA, deserves special credit for having prepared these Guidelines. The key professional staff, Dr. Christopher Murrill and Dr. Rebecca Martin, should be congratulated for their efforts in producing this document, with editorial assistance from Ms. Sadhna Patel and Ms. Beatrice Divine." - p. iiAlso available via the World Wide Web.Includes bibliographical references (p. 37-38)